USP Changes Heparin Labeling Requirement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Changes Heparin Labeling Requirement


ePT--the Electronic Newsletter of Pharmaceutical Technology

The United States Pharmacopeial Convention (USP) has revised its current labeling standards for heparin sodium injections and heparin lock flush solutions to address safety concerns about the expression of the drugs’ strength. USP said in a press release that a misunderstanding of the expression of total strength on multidose product labels might cause errors that could lead to serious consequences to patients. According to USP, the change in labeling will mostly impact heparin multiple-dose vials.

The new standards, which go into effect on May 1, 2013, are addressed in the labeling sections of the Heparin Sodium Injection and Heparin Lock Flush Solution monographs in the United States Pharmacopeia/National Formulary (USP/NF). The monographs are being revised to comply with USP/NF General Chapter <1> Injections, which requires “that the label reflect strength per total volume as the primary expression of strength followed in close proximity by strength per mL.”

The revision addresses a 2010 letter from FDA to USP expressing concern that healthcare practitioners often misunderstood product labels with strength statements written as “mg per mL” as total drug content statements, which could lead to improper patient dosing. USP’s Safe Medication Use Expert Committee reviewed FDA’s concerns.

In the press release, Roger L. Williams, USP’s CEO, said, “USP is committed to developing standards that help to advance public health. It is our goal to ensure that USP standards aid practitioners in their delivery of quality care to patients. Particularly in light of the public health emergency involving adulterated heparin in 2008, USP and FDA are continuing to work closely together to help ensure that heparin delivery is as safe and accurate as possible.”

USP will post the official monographs in the “Official Text” section on its website on Jan. 25, 2013.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here